Chemotherapy Plus Immune Checkpoint Inhibitor With or Without Bevacizumab After Disease Progression With First-line Alectinib of Advanced ALK-rearranged Non-small Cell Lung Cancer With 5'-ALK
Latest Information Update: 28 May 2024
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Immune checkpoint protein inhibitors (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CLASSIC5
- 02 Apr 2024 Study design is changed from cohort, retrospective, observational to open, parallel, interventional. Treatment arms are added and upper age limit for inclusion criteria is added as 75 years.
- 17 Aug 2021 New trial record